These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 15475067)

  • 1. Nonclonal neutrophil responses after successful treatment of myelodysplasia with low-dose 5-aza-2'-deoxycytidine (decitabine).
    Lübbert M; Daskalakis M; Kunzmann R; Engelhardt M; Guo Y; Wijermans P
    Leuk Res; 2004 Dec; 28(12):1267-71. PubMed ID: 15475067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo effects of decitabine in myelodysplasia and acute myeloid leukemia: review of cytogenetic and molecular studies.
    Hackanson B; Robbel C; Wijermans P; Lübbert M
    Ann Hematol; 2005 Dec; 84 Suppl 1():32-8. PubMed ID: 16292549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superiority of prolonged low-dose azanucleoside administration? Results of 5-aza-2'-deoxycytidine retreatment in high-risk myelodysplasia patients.
    Rüter B; Wijermans PW; Lübbert M
    Cancer; 2006 Apr; 106(8):1744-50. PubMed ID: 16532502
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of myelodysplastic syndrome with a DNA methyltransferase inhibitor: lack of evidence for induction of chromosomal instability.
    Haas PS; Wijermans P; Verhoef G; Lübbert M
    Leuk Res; 2006 Mar; 30(3):338-42. PubMed ID: 16162357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An epigenetic approach to the treatment of advanced MDS; the experience with the DNA demethylating agent 5-aza-2'-deoxycytidine (decitabine) in 177 patients.
    Wijermans PW; Lübbert M; Verhoef G; Klimek V; Bosly A
    Ann Hematol; 2005 Dec; 84 Suppl 1():9-17. PubMed ID: 16211386
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2'-deoxycytidine.
    Lübbert M; Wijermans P; Kunzmann R; Verhoef G; Bosly A; Ravoet C; Andre M; Ferrant A
    Br J Haematol; 2001 Aug; 114(2):349-57. PubMed ID: 11529854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: a claims database study.
    Hatoum HT; Lin SJ; Buchner D; Kim E
    Curr Med Res Opin; 2011 Jun; 27(6):1255-62. PubMed ID: 21554144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 5-Aza-2'-deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes.
    Zagonel V; Lo Re G; Marotta G; Babare R; Sardeo G; Gattei V; De Angelis V; Monfardini S; Pinto A
    Leukemia; 1993 May; 7 Suppl 1():30-5. PubMed ID: 7683354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous infusion of low-dose 5-Aza-2'-deoxycytidine in elderly patients with high-risk myelodysplastic syndrome.
    Wijermans PW; Krulder JW; Huijgens PC; Neve P
    Leukemia; 1997 Mar; 11 Suppl 1():S19-23. PubMed ID: 9130687
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome.
    Mund C; Hackanson B; Stresemann C; Lübbert M; Lyko F
    Cancer Res; 2005 Aug; 65(16):7086-90. PubMed ID: 16103056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-intensive treatment with low-dose 5-aza-2'-deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients.
    Lübbert M; Bertz H; Rüter B; Marks R; Claus R; Wäsch R; Finke J
    Bone Marrow Transplant; 2009 Nov; 44(9):585-8. PubMed ID: 19363531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of 5-aza-2'-deoxycytidine on proliferation, differentiation and p15/INK4b regulation of human hematopoietic progenitor cells.
    Guo Y; Engelhardt M; Wider D; Abdelkarim M; Lübbert M
    Leukemia; 2006 Jan; 20(1):115-21. PubMed ID: 16307025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study.
    Hu N; Qin T; Du X; Wang B; Wang X; Xu Z; Pan L; Qu S; Xiao Z
    Med Sci Monit; 2021 Jan; 27():e928454. PubMed ID: 33514682
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of prolonged treatment of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor.
    Greenberg P; Negrin R; Nagler A; Vincent M; Donlon T
    Int J Cell Cloning; 1990 Jan; 8 Suppl 1():293-300; discussion 300-2. PubMed ID: 1691248
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A limited number of 5-azacitidine cycles can be effective treatment in MDS.
    Müller-Thomas C; Schuster T; Peschel C; Götze KS
    Ann Hematol; 2009 Mar; 88(3):213-9. PubMed ID: 18696067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia.
    Cermák J; Belicková M; Krejcová H; Michalová K; Zilovcová S; Zemanová Z; Brezinová J; Sieglová Z
    Leuk Res; 2005 Apr; 29(4):371-9. PubMed ID: 15725470
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hematologic outcomes of myelodysplastic syndromes treatment with hypomethylating agents in community practice.
    Bordoni RE; Feinberg BA; Gilmore JW; Haislip S; Jackson JH; Farrelly E; Kim E; Buchner D
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):350-4. PubMed ID: 21816373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment with very low-dose GM-CSF in myelodysplastic syndromes with neutropenia. A report on 28 cases.
    Rose C; Wattel E; Bastion Y; Berger E; Bauters F; Coiffier B; Fenaux P
    Leukemia; 1994 Sep; 8(9):1458-62. PubMed ID: 8090025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I trial of sequential low-dose 5-aza-2'-deoxycytidine plus high-dose intravenous bolus interleukin-2 in patients with melanoma or renal cell carcinoma.
    Gollob JA; Sciambi CJ; Peterson BL; Richmond T; Thoreson M; Moran K; Dressman HK; Jelinek J; Issa JP
    Clin Cancer Res; 2006 Aug; 12(15):4619-27. PubMed ID: 16899610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytogenetic effects on cells derived from patients with myelodysplastic syndromes during treatment with hemopoietic growth factors.
    Verhoef G; Van den Berghe H; Boogaerts M
    Leukemia; 1992 Aug; 6(8):766-9. PubMed ID: 1640727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.